Bold capacity investments lag despite urgent need for decentralised pharma supply chains - Roland Berger

“What we’re witnessing is a fundamental shift from globalized to decentralized pharma supply chains, yet many companies are hesitant to make the bold capacity investments needed despite recognizing the risks.” – Stephan Fath, Director at Roland Berger

Stephan Fath is a Director at Roland Berger where he specialises in advising global pharmaceutical, MedTech, and chemical industries. With a dual degree in Business Administration and Chemistry from the University of Dusseldorf, Stephan brings a valuable interdisciplinary perspective to network strategy challenges.

In the latest PharmaSource podcast episode, Stephan shares critical insights into how pharmaceutical manufacturing networks are evolving in 2025, highlighting the delicate balance companies must strike between cost efficiency, supply chain resilience, and technological innovation in an increasingly uncertain global landscape.

Read the full article